Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

KOL Knockout: Headache Edition: Novel Preventative and Acute Therapies for Migraine

By: Paul G. Mathew, MD, DNBPAS, FAAN, FAHS; Meridith Barad, MD; Wade Cooper, DO; Stephanie Nahas-Geiger MD; and Umer Najib, MD

Webinar Credits: 1

Several novel therapies, including pharmacological agents and devices, for the treatment of migraine have recently entered the market and additional therapies are on the horizon. These therapies offer options for patients who have migraine that is refractory to treatment or who are unable to use existing migraine treatments due to tolerability issues or contraindications.

Expiration Date: Tuesday, August 31, 2021
Release Date: September 2020

Learning Objectives

This initiative is designed to address and resolve the educational needs through the following educational objectives:

  • Diagnose migraine comorbidities and coexisting headache disorders, appraise the available tools and execute management strategies for these conditions.
  • Recognize patients who are in need of preventive therapy for migraines and distinguish among existing and novel preventive therapies for migraine, specifically CGRP-antibodies and their mechanism of their action.
  • Rate acute medication options for treatment of migraine, including the newer acute therapies, ubrogepant, rimegepant and lasmiditan, and explain their mechanism of action and the indications for their use.
  • Compare neuro-modulatory devices that are approved for use in treatment of migraine and the indications for their use.

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve Medical Education LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
-Internet Explorer 11 for Windows
-Edge (recent versions; Chromium-based) for Windows
-Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
-Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
-Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
-4GB+ RAM
-Recommended internet speed 5Mbps+

Faculty and Disclosures


Paul G. Mathew, MD, DNBPAS, FAAN, FAHS
Program Moderator
Assistant Professor of Neurology
Harvard Medical School
Headache/Sports Neurology/Concussion Specialist
Brigham and Women’s Hospital/
Harvard Vanguard Medical Associates
Boston, MA

 

Meredith Barad, MD
Clinical Associate Professor, Anesthesia (Pain Medicine),
and Neurology & Neurological Sciences
Program Director and Associate Division Chief, Pain Education
Stanford Hospital and Clinics
Redwood City, CA

 

Wade Cooper, DO
Clinical Associate Professor, Neurology and Anesthesiology
Director, Headache & Neuropathic Pain
University of Michigan
Ann Arbor, MI

 

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN
Director, Headache Medicine
Fellowship Program
Associate Professor,
Department of Neurology
Thomas Jefferson University
Jefferson Headache Center
Philadelphia, PA

 

Umer Najib, MD, FAHS
Associate Professor of Neurology
Director, WVU Headache Center
Program Director,
Headache Medicine Fellowship
Rockefeller Neuroscience Institute
West Virginia University
Morgantown, WV

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:
Paul G. Mathew, MD, DNBPAS, FAAN, FAHS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Amgen, Biohaven Pharmaceuticals, Eli Lilly, Supernus, Theranica, and Teva.

Meredith Barad, MD, and/or spouse/partner has no financial agreements or affiliation during the past year with commercial interests.

Wade Cooper, DO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Amgen, Biohaven Pharmaceuticals, Dolor Technologies, Eli Lilly, Lundbeck, Teva, and Theranica. Stock/Shareholder: Dolor Technologies.

Stephanie Nahas, MD, MSEd, FAHS, FAAN, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan/Abbvie, Amgen/Novartis, Biohaven Pharmaceuticals, Eli Lilly, Impel, Supernus, Teva, Theranica, Vorso Corp, and Zosano. Speaker’s Bureau: Allergan/Abbvie, Amgen/Novartis, electroCore, Eli Lilly, Supernus, and Teva.

Umer Najib, MD, FAHS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker’s Bureau: Allergan.

The Evolve staff and planners have no financial relationships with commercial interests.

Bernard Abrams, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Biohaven Pharmaceuticals.

Pretest

  • a. Not at all confidentb. Not very confidentc. Neutrald. Confidente. Extremely confident

Video Resources

Next

Test

Instructions

Step 1 of 2

  • a. Not at all confidentb. Not very confidentc. Neutrald. Confidente. Extremely confident
  • AgreeNeutralDisagree
    Diagnose migraine comorbidities and coexisting headache disorders, appraise the available tools and execute management strategies for these conditions.
    Recognize patients who are in need of preventive therapy for migraines and distinguish among existing and novel preventive therapies for migraine, specifically CGRP-antibodies and their mechanism of their action.
    Rate acute medication options for treatment of migraine, including the newer acute therapies, ubrogepant, rimegepant and lasmiditan, and explain their mechanism of action and the indications for their use.
    Compare neuro-modulatory devices that are approved for use in treatment of migraine and the indications for their use.
Back